PMC10424197_01
1A. Postero-anterior chest x-ray demonstrating the cavitary lung mass in the left upper lobe (white arrow). 1B. Non-contrast Computed Tomograghy demonstrating cavitated lung mass in the left upper lobe (3.7 x 2.6cm) without enlarged mediastinal or hilar lymphadenopathy.
gr1.jpg
PMC10424197_01_gr1.jpg
fig1
A chest x-ray and computed tomography (CT) revealed a cavitated left upper lobe lung (LUL) mass measuring 3.7 x 2.6 cm without pathologic enlarged mediastinal lymphadenopathy (Fig. 1).
Positron emission tomography-computed tomography. Three areas with hypermetabolic activity: Lung mass in the left upper lobe; posterior FDG-avid nodule; posterolateral FDG-avid nodule.
gr2.jpg
PMC10424197_01_gr2.jpg
fig2
LUL mass (SUVmax 17.4); pleural-based focus, medial aspect of the posterior left lower hemithorax (SUVmax 3.3); and pleural-based focus, more lateral aspect of the posterior left lower hemithorax (SUVmax 5.7) (Fig. 2).
Lung ultrasound. Diaphragm (narrow white arrow), pleural nodule (thick white arrow). Distance measurements are represented by the dotted lines: (A) skin to diaphragm, (B) skin to lung, (C) size of lung nodule. Diaphragm thickness is > 1 cm, which has a high diagnostic sensitivity for the presence of a malignant pleural effusion regardless of if cytology is negative.
gr3.jpg
PMC10424197_01_gr3.jpg
fig3
Argon Medical Devices, Inc, USA) was passed four times at the same angle of the US probe (Fig. 3). A thoracentesis was subsequently performed, with a total of 20mL pleural fluid drained.